RhumbLine Advisers
BRNS

RhumbLine Advisers’s Barinthus Biotherapeutics BRNS Stock Holding History

RhumbLine Advisers’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.71K Hold
11,685
– – ﹤0.01% 3929
2026
Q1 		$6.68K Hold
11,685
– – ﹤0.01% 3847
2025
Q4 		$8.18K Buy
+11,685
New +$11.7K ﹤0.01% 3877
2025
Q1 		– Sell
-60
Closed -$72 – 4137
2024
Q4 		$72 Hold
60
– – ﹤0.01% 4142
2024
Q3 		$73 Hold
60
– – ﹤0.01% 4173
2024
Q2 		$84 Hold
60
– – ﹤0.01% 4339
2024
Q1 		$144 Hold
60
– – ﹤0.01% 4227
2023
Q4 		$213 Hold
60
– – ﹤0.01% 4233
2023
Q3 		$185 Buy
+60
New +$129 ﹤0.01% 4271

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
GP
GLR Partners Columbia, Maryland $215M AUM
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.5B AUM 13.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

RhumbLine Advisers's BRNS Position: Q2 2026 in Review

RhumbLine Advisers held its Barinthus Biotherapeutics (BRNS) position steady in Q2 2026 at 11,685 shares worth $7.71K. The position accounts for ﹤0.01% of the portfolio, ranked #3929.

RhumbLine Advisers first reported a position in BRNS in Q3 2023 and has held it in 9 quarters since. The position peaked at $8.18K in Q4 2025. 15 funds tracked by Wall St. Rank hold BRNS as of Q2 2026.

  • RhumbLine Advisers held 11,685 shares of Barinthus Biotherapeutics worth $7.71K as of Q2 2026.
  • RhumbLine Advisers left its Barinthus Biotherapeutics share count unchanged in Q2 2026.
  • Barinthus Biotherapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3929 holding.
  • RhumbLine Advisers first reported a position in Barinthus Biotherapeutics in Q3 2023 and has held it in 9 quarters since.
  • RhumbLine Advisers's Barinthus Biotherapeutics position peaked at $8.18K in Q4 2025.
  • 15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.